Skip to main content
Fig. 2 | Cancer Imaging

Fig. 2

From: The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

Fig. 2

A 73-year-old man with squamous cell lung cancer, who had marked metabolic changes on 18F-FDG PET/CT where evaluated as PMR according to PERCIST after three cycles pembrolizumab added to nab-paclitaxel plus cisplatin treatment. (A)The scan-1axial fusion image of lung cancer, SULpeak = 10.0. (B)The scan-2axial fusion image of lung cancer after neoadjuvant therapy, SULpeak = 5.5; ΔSULpeak% = − 45.2%. (C)The surgical pathology showed that MPR was achieved (The residual viable tumor was 5%, less than 10%)

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us